2022
Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials
Shurtz L, Schwartz C, DiStefano C, McPartland JC, Levin AR, Dawson G, Kleinhans NM, Faja S, Webb SJ, Shic F, Naples AJ, Seow H, Bernier RA, Chawarska K, Sugar CA, Dziura J, Senturk D, Santhosh M, Jeste SS. Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials. Autism 2022, 27: 952-966. PMID: 36086805, PMCID: PMC9995606, DOI: 10.1177/13623613221121425.Peer-Reviewed Original ResearchConceptsConcomitant psychotropic medicationsPsychotropic medicationsClinical trialsMedication useSchool-aged childrenClinical representativenessSelective serotonin reuptake inhibitorsConcomitant medication useVariety of medicationsAutism spectrum disorderSerotonin reuptake inhibitorsPsychotropic medication useNew treatment optionsGreater overall impairmentCentral nervous systemSpectrum disorderMedication classesReuptake inhibitorsAlpha agonistsTreatment optionsClinical endpointsInclusion criteriaStudy populationMedicationsNervous system
2021
Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation
Edelman EJ, Gan G, Dziura J, Esserman D, Morford KL, Porter E, Chan PA, Cornman DH, Oldfield BJ, Yager JE, Muvvala SB, Fiellin DA. Readiness to Provide Medications for Addiction Treatment in HIV Clinics: A Multisite Mixed-Methods Formative Evaluation. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2021, 87: 959-970. PMID: 33675619, PMCID: PMC8192340, DOI: 10.1097/qai.0000000000002666.Peer-Reviewed Original ResearchConceptsHIV clinicTreatment medicationsMixed-methods formative evaluationAddiction treatmentTreatment-eligible patientsSubscale scoresAddiction treatment medicationsAdverse health consequencesHIV careMedication complexityTobacco useMedicationsClinicHealth consequencesSite specialistMultidisciplinary teamworkBehavioral servicesTreatment modelOpioidsLocal championsVariable experienceInconsistent availabilityAddiction treatment modelsFocus groupsTreatment
2020
Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study
Edelman EJ, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Rebick G, Yager J, Morford K, Muvvala SB, Fiellin DA. Working with HIV clinics to adopt addiction treatment using implementation facilitation (WHAT-IF?): Rationale and design for a hybrid type 3 effectiveness-implementation study. Contemporary Clinical Trials 2020, 98: 106156. PMID: 32976995, PMCID: PMC7511156, DOI: 10.1016/j.cct.2020.106156.Peer-Reviewed Original ResearchConceptsHIV clinicImplementation facilitationAddiction treatmentHealth services research frameworkHybrid type 3Effectiveness-implementation studyEvidence-based counselingSubstantial morbidityClinical outcomesOpioid misusePromoting ActionEffectiveness outcomesClinicFacilitators of integrationType 3Implementation outcomesTreatmentOutcomesWedge designHIVResearch implementationStudy goalFacilitation studiesStaff readinessMedications
2016
Increase in migraine diagnoses and guideline-concordant treatment in veterans, 2004–2012
Altalib H, Fenton B, Sico J, Goulet J, Bathulapalli H, Mohammad A, Kulas J, Driscoll M, Dziura J, Mattocks K, Kerns R, Brandt C, Haskell S. Increase in migraine diagnoses and guideline-concordant treatment in veterans, 2004–2012. Cephalalgia 2016, 37: 3-10. PMID: 26950804, DOI: 10.1177/0333102416631959.Peer-Reviewed Original ResearchConceptsBurden of migraineMigraine diagnosisVeterans Health Administration electronic health recordsGuideline-concordant treatmentGuideline-concordant careMigraine-specific medicationsICD-9 codesChi-square testHealth care systemNumber of veteransElectronic health recordsTriptan prescriptionMigraine preventionGuideline adherenceMigraine medicationsComorbid conditionsNational health care systemMigraine headacheMedicationsMigraineTime-series studyLogistic regressionCare systemPreventive medicineHealth administrators
2014
Sex Differences in Patient and Provider Response to Elevated Low-Density Lipoprotein Cholesterol
Haskell SG, Bathulapalli H, Pham T, Goulet J, Skanderson M, Driscoll M, Brandt C, Dziura J. Sex Differences in Patient and Provider Response to Elevated Low-Density Lipoprotein Cholesterol. Women's Health Issues 2014, 24: 575-580. PMID: 25213750, DOI: 10.1016/j.whi.2014.06.004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticholesteremic AgentsAttitude of Health PersonnelAttitude to HealthDyslipidemiasElectronic Health RecordsFemaleHealthcare DisparitiesHumansLipoproteins, LDLLogistic ModelsMaleMiddle AgedOdds RatioPractice Patterns, Physicians'Risk FactorsSex FactorsTreatment OutcomeUnited StatesConceptsCholesterol controlElevated LDLLow-density lipoprotein cholesterol controlElevated low-density lipoprotein cholesterolLow-density lipoprotein cholesterolProvider responsesAmerican Heart Association recommendationsLipid-lowering medicationsIschemic heart diseaseDiet/lifestyle modificationLifestyle modificationStatin therapyLipoprotein cholesterolPatient factorsPatient sexRisk womenClinical remindersHeart diseaseWomen patientsPatient responseTreatment goalsAssociation recommendationsLDL elevationsMedicationsWomen veterans
2009
Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial
Aman MG, Mcdougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, Stigler KA, Bearss K, Butter E, Swiezy NB, Sukhodolsky DD, Ramadan Y, Pozdol SL, Nikolov R, Lecavalier L, Kohn AE, Koenig K, Hollway JA, Korzekwa P, Gavaletz A, Mulick JA, Hall KL, Dziura J, Ritz L, Trollinger S, Yu S, Vitiello B, Wagner A, Network F. Medication and Parent Training in Children With Pervasive Developmental Disorders and Serious Behavior Problems: Results From a Randomized Clinical Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 1143-1154. PMID: 19858761, PMCID: PMC3142923, DOI: 10.1097/chi.0b013e3181bfd669.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical trialsClinical Global Impressions-Improvement scoreAberrant Behavior Checklist IrritabilityParallel-group clinical trialParent trainingBehavioral problemsDevelopmental disordersRisperidone doseRisperidone monotherapyHyperactivity/noncompliance subscaleSevere behavioral problemsCOMB groupPT sessionsQuestionnaire scoresHSQ scoresMedicationsGreater reductionChildrenPrimary measureRisperidoneSignificant reductionStereotypic behaviorScoresDose
2008
Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders
Scahill L, Aman MG, McDougle CJ, Arnold LE, McCracken JT, Handen B, Johnson C, Dziura J, Butter E, Sukhodolsky D, Swiezy N, Mulick J, Stigler K, Bearss K, Ritz L, Wagner A, Vitiello B. Trial Design Challenges When Combining Medication and Parent Training in Children with Pervasive Developmental Disorders. Journal Of Autism And Developmental Disorders 2008, 39: 720-729. PMID: 19096921, PMCID: PMC4807607, DOI: 10.1007/s10803-008-0675-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAggressionBehavior TherapyChildChild Development Disorders, PervasiveCombined Modality TherapyDopamine AntagonistsFemaleHumansMaleOutpatientsParent-Child RelationsParentsPatient CompliancePersonality AssessmentPsychiatric Status Rating ScalesRisperidoneSelf-Injurious BehaviorTreatment OutcomeConceptsParent trainingAdaptive functioningPervasive developmental disorderMeasures of noncomplianceBehavioral interventionsSymptom reductionDevelopmental disordersTraining targetClinical treatment targetsTrial design challengesTreatment targetsFunctioningTrainingFunctional improvementLow doseTreatment groupsMedicationsClinical practiceTantrumsAggressionBeneficial effectsIrritabilityChildrenNoncomplianceDisorders